The drug being tested in this study is called niraparib. Niraparib is being tested to treat
people who have the homologous recombination deficiency (HRD)-positive, advanced, relapsed,
high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. This
study will look at the efficacy and safety of niraparib in Japanese participants.
The study will enroll approximately 16 participants. Participants will be enrolled to one
group and after that will be asked to take niraparib capsules at the same time each day
throughout the study:
・Niraparib 300 mg
This multi-center trial will be conducted in Japan. The overall time to participate in this
study is approximately 23 months. Participants will make multiple visits to the clinic in the
treatment period, and the post-treatment period including follow-up assessments after the
last dose of the study drug.
1. Japanese female participants aged 20 years or older on the day of signing informed
2. Voluntary written consent must be given before performance of any study related
procedure not part of standard medical care, with the understanding that consent may
be withdrawn by the participant at any time without prejudice to future medical care.
3. Participants must agree to undergo tumor HRD testing, and this test result must show
that participants have an HRD-positive tumor (defined by the presence of a deleterious
or suspected deleterious breast cancer gene (BRCA) mutation or be positive for genomic
instability) by the central laboratory selected by the sponsor.
Note 1: The study HRD test result must be received prior to enrollment. The tumor
sample may be submitted for HRD testing prior to the screening period (ie, within 40
days before Cycle 1 Day 1) if the consent has been obtained and it appears the
participant is likely to meet other eligibility requirements.
Note 2: If historic blood germline BRCA mutation (gBRCAmut) is detected by a prior
gBRCAmut testing, then tumor HRD sample test results are not required prior to
enrollment; however, HRD testing still needs to be performed.
4. Participants must have histologically diagnosed, relapsed, high-grade (Grade 2 or 3)
serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with recurrent
disease and must have been previously treated with chemotherapy and have not
experienced disease progression at least 6 months to the last chemotherapy containing
platinum-based anticancer agents.
5. Participants must have completed 3 or 4 previous chemotherapy regimens. Participants
must have completed their last chemotherapy regimen >4 weeks prior to treatment
6. Participants must have at least one measurable disease according to RECIST (v.1.1).
7. Participants must have performance status of ≤1 on the Eastern Cooperative Oncology
Group (ECOG) Performance Status Scale.
8. Participants must have adequate organ function as indicated by the following
1. Absolute neutrophil count (ANC) ≥1,500/μL.
2. Platelet count ≥150,000/μL.
3. Hemoglobin ≥10 g/dL.
4. Serum creatinine ≤1.5× institutional upper limit of normal (ULN) OR calculated
creatinine clearance ≥50 mL/minute, using the Cockcroft-Gault equation.
5. Total bilirubin ≤1.5×ULN OR direct bilirubin ≤1×ULN.
6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN
unless liver metastases were present, in which case they had to be ≤5×ULN.
9. Participants must have formalin-fixed, paraffin-embedded tumor samples available from
the primary or recurrent cancer or agree to undergo fresh biopsy prior to study
10. Participants must be able to take oral medications.
11. Female participants of childbearing potential must be negative for pregnancy test
(beta-human chorionic gonadotropin [β-hCG]) within 7 days prior to receiving the first
dose of study treatment.
12. Female participants who:
1. Are postmenopausal for at least 1 year before the screening visit, OR
2. Are surgically sterile, OR
3. If they are of childbearing potential, agree to practice 1 highly effective
method of contraception and 1 additional effective (barrier) method at the same
time, from the time of signing the informed consent through 180 days after the
last dose of study drug, OR
4. Agree to practice true abstinence, when this is in line with the preferred and
usual lifestyle of the participant. (Periodic abstinence [eg, calendar,
ovulation, symptothermal, postovulation methods], condoms only, withdrawal,
spermicides only, and lactational amenorrhea are not acceptable methods of
contraception. Female and male condoms should not be used together.)
1. Participants who have had palliative radiotherapy encompassing >20% of the bone marrow
within 1 week of the first dose of study treatment.
2. Participants who have any known, persistent (>4 weeks), Grade ≥3 hematologic toxicity
from last cancer therapy.
3. Participants who have any known, persistent (>4 weeks), Grade ≥3 fatigue during the
last cancer therapy.
4. Participants who have received pelvic radiotherapy as treatment for primary or
recurrent disease within 1 year of the first dose of study treatment.
5. Participants who have symptomatic, uncontrolled brain or leptomeningeal metastases.
To be considered "controlled," central nervous system (CNS) disease must have
undergone treatment (eg, radiation or chemotherapy) at least 1 month prior to study
enrollment. The participant must not have had any new or progressive signs or symptoms
related to the CNS disease and must have been taking a stable dose of steroids or no
steroids (as long as these were started at least 4 weeks prior to enrollment] or no
steroids). A scan to confirm the absence of brain metastases at baseline was not
required. Participants with spinal cord compression might have been considered if they
had received definitive treatment for this and evidence of clinically stable disease
for 28 days.
6. Participants who have known hypersensitivity to the components of niraparib.
7. Participants who have had prior treatment with a known poly (adenosine diphosphate
[ADP]-ribose) polymerase (PARP) inhibitors.
8. Participant who have had treatment with any investigational products within 28 days or
5 half-lives (whichever was longer) before the first dose.
9. Participants who have had major surgery per Investigator judgment within 3 weeks of
the first dose. Participant must have recovered from any effects of any major surgery.
10. Participants who have diagnosis, detection, or treatment of invasive second primary
malignancy other than ovarian cancer ≤24 months prior to study enrollment (except
basal or squamous cell carcinoma of the skin that was definitively treated). Note:
Participants must not have any known history or current diagnosis of myelodysplastic
syndrome (MDS) or acute myeloid leukemia (AML), irrespective of the time for disease
11. Participants who are considered a poor medical risk due to a serious, uncontrolled
medical disorder, non-malignant systemic disease, or active, uncontrolled infection.
Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent
(within 90 days of the first dose) myocardial infarction, uncontrolled major seizure
disorder, unstable spinal cord compression, superior vena cava syndrome, small bowel
obstruction or other serious gastrointestinal disorder, or any psychiatric disorder
that prohibits obtaining informed consent.
12. Participants who have received a transfusion (platelets or red blood cells) within 4
weeks of the first dose of study treatment.
13. Participants who have received a live virus or bacterial vaccines within 4 weeks of
the first dose of study treatment.
14. Participants who have a history or current evidence of any condition, therapy, or lab
abnormality (including active or uncontrolled myelosuppression [ie, anemia,
leukopenia, neutropenia, thrombocytopenia]) that might confound the results of the
study, interfere with the participant's participation throughout the study period, or
study participation is not in the best interest of the participant.
15. Participants who are regular user (including "recreational use") of any illicit drugs
at the time of signing informed consent or have a recent history (within the past
year) of drug or alcohol abuse.
16. Participants who are pregnant or breast-feeding, or expecting to conceive within the
planned duration of the study.
NOTE: If a breast-feeding woman discontinue breast-feeding, she may be enrolled in the
17. Participants who are immunocompromised (participants with splenectomy are allowed).
18. Participants who have known human immunodeficiency virus (HIV) positive.
19. Participants who have known hepatitis B surface antigen (HBsAg) positive, or known or
suspected active hepatitis C virus (HCV) infection.
NOTE: Participants who are positive for hepatitis B core antibody (HBcAb) or hepatitis B
surface antibody (HBsAb) can be enrolled but must have an undetectable hepatitis B virus
(HBV) viral load. Participants who have positive hepatitis C virus antibody (HCVAb) must
have an undetectable HCV viral load.